|
3rd International AIDS Society Conference on HIV Pathogenesis and TreatmentRio de Janeiro - July 24 - 27, 2005 |
HIV SEROINCIDENCE ESTIMATES AMONG VULNERABLE POPULATIONS IN BUENOS AIRES USING A SEROLOGIC TESTING ALGORITHM FOR RECENT HIV SEROCONVERSION
IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. MoOa0102
Vignoles M.1, Avila M.M.1, Martínez Peralta L.1, Pando M.D.L.A.1, Sheppard H.2, Maulen S.3, Radulich G.4, Rossi D.5, Muzzio E.6, Benetucci J.7, Weissenbacher M.1
1National Reference Center for AIDS, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina, 2Viral and Rickettsial Disease Laboratory, Richmond, United States of America, 3NEXO Asociación CiviL, Buenos Aires, Argentina, 4Asociación El Retoño, Buenos Aires, Argentina, 5Intercambios Asociación Civil, Buenos Aires, Argentina, 6CENARESO, Buenos Aires, Argentina, 7Muñiz Hospital, Buenos Aires, Argentina
INTRODUCTION: The aim of this study was to estimate the incidence of HIV-1 infection in populations with different routes of transmission where few or no incidence studies have been carried out, using the STARHS.
METHODS: Serum samples from 6 HIV seroprevalence surveys, conducted in Buenos Aires in different populations were used. These were: men who have sex with men (MSM), injecting drug users (IDU), asymptomatic women consulting for an HIV infection (AW), heterosexual individuals consulting about new sexually transmitted infections (STI), individuals with tuberculosis (TB), and non-injecting cocaine users (NICU). HIV-1 seropositive were tested with the modified Vironostika HIV-1 Microelisa System. Using a window period of 170 days and cut-off: 1.0 annual incidence estimates were calculated with STARHS.
RESULTS:
| Population | MSM | IDU | STI | NICU | TB |
| Year | 2000-2001 | 2000-2001 | 2001-2002 | 2002-2003 | 2001-2002 |
| Sample # | 694 | 174 | 801 | 504 | 211 |
| HIV-positive | 96 | 77 | 58 | 32 | 35 |
| Adjusted annual HIV seroincidence (per 100 person-years) (95% CI) | 6.7 (3.7-9.7) | 0.0 (--) | 2.0 (0.5-3.5) | 3.1 (0.8-5.5) | 2.4 (0.0-5.8) |
| HIV seroprevalence (%) (95% CI) | 13.8 (11.4-16.7) | 44.3 (36.8-52.0) | 7.2 (5.6-9.3) | 6.3 (4.4-8.9) | 16.6 (12.0-22.4) |
| Population | AW | AW | AW |
| Year | 1998 | 1999 | 2000 |
| Sample # | 716 | 660 | 566 |
| HIV-positive | 71 | 80 | 93 |
| Adjusted annual HIV seroincidence (per 100 person-years) (95% CI) | 0.4 (0.0-1.1) | 4.6 (2.1-7.1) | 10.2 (6.0-14.3) |
| HIV seroprevalence (%) (95% CI) | 9.9 (7.9-12.4) | 12.1 (9.8-14.9) | 16.4 (13.5-19.8) |
Conclusions: The high HIV incidence found in some vulnerable populations from Buenos Aires indicate the urgent need for planning specific prevention strategies for them, mainly for MSM, NICUs and AW. STARHS-estimated incidence among MSM was confirmed with a longitudinal cohort study during the same period of time [Incidence: 6.0%person/year (3.1-11.0)]. Some of the groups with high HIV incidence may be considered suitable for volunteer participation in HIV vaccine clinical trials.
Download PDF of this abstract.
Download Power Point Presentation.
050724
Prevention | MoOa0102 | Moira Vignoles
10.2 97 10.2 HIV incidence measurement
Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.
AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.